147 related articles for article (PubMed ID: 6895353)
1. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
Hardisty CA; Hanford L; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
[TBL] [Abstract][Full Text] [Related]
2. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
Hardisty CA; Fowles A; Munro DS
J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
[TBL] [Abstract][Full Text] [Related]
3. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
Hardisty CA; Hanford L; Munro DS
Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
[TBL] [Abstract][Full Text] [Related]
4. Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.
Adams DD; Kennedy TH; Stewart RD
Br Med J; 1974 Apr; 2(5912):199-201. PubMed ID: 4406686
[TBL] [Abstract][Full Text] [Related]
5. Do thyroid-stimulating immunoglobulins cause non-toxic and toxic multinodular goitre?
Brown RS; Jackson IM; Pohl SL; Reichlin S
Lancet; 1978 Apr; 1(8070):904-6. PubMed ID: 76846
[TBL] [Abstract][Full Text] [Related]
6. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS).
Chopra IJ; Solomon DH; Limberg NP
J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701
[No Abstract] [Full Text] [Related]
7. The assay of Graves' immunoglobulins: a comparison of different methods.
Hardisty CA; Kendall-Taylor P; Atkinson S; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1983 Jun; 18(6):637-44. PubMed ID: 6136348
[TBL] [Abstract][Full Text] [Related]
8. The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.
Hardisty CA; Fowles A; Munro DS
Clin Endocrinol (Oxf); 1984 May; 20(5):597-605. PubMed ID: 6547647
[TBL] [Abstract][Full Text] [Related]
9. Serum long acting thyroid stimulator protector in pregnancy complicated by Graves' disease.
Hardisty CA; Munro DS
Br Med J (Clin Res Ed); 1983 Mar; 286(6369):934-5. PubMed ID: 6403139
[TBL] [Abstract][Full Text] [Related]
10. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
[TBL] [Abstract][Full Text] [Related]
11. LATS-protector activity in thyrotoxicosis measured by thyroidal intracellular colloid droplet formation.
Shishiba Y; Miyachi Y; Takaishi M; Ozawa Y
J Clin Endocrinol Metab; 1978 May; 46(5):841-8. PubMed ID: 262769
[TBL] [Abstract][Full Text] [Related]
12. Long-acting thyroid stimulator (LATS) in toxic nodular goitre, toxic adenoma and Graves' disease.
Lamberg BA; Gordin A; Viherkoski M; Kvist G
Acta Endocrinol (Copenh); 1969 Oct; 62(2):199-209. PubMed ID: 5394703
[No Abstract] [Full Text] [Related]
13. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
[TBL] [Abstract][Full Text] [Related]
14. Concentration of long-acting thyroid stimulator (LATS) by subfractionation of gamma G globulin from Graves' disease serum.
Miyai K; Werner SC
J Clin Endocrinol Metab; 1966 May; 26(5):504-12. PubMed ID: 5952570
[No Abstract] [Full Text] [Related]
15. Placental transmission of thyroid-stimulating immunoglobulins.
Dirmikis SM; Munro DS
Br Med J; 1975 Jun; 2(5972):665-6. PubMed ID: 1173561
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of thyroidal iodothyronine 5'-monodeiodinase by long-acting thyroid stimulator (LATS).
Wu SY; Reggio R; Florsheim W; Chopra IJ; Solomon DH
Acta Endocrinol (Copenh); 1987 Feb; 114(2):193-200. PubMed ID: 3825441
[TBL] [Abstract][Full Text] [Related]
17. [Human thyroid stimulator (HTS) in thyroid diseases].
Hu ZY
Zhonghua Nei Ke Za Zhi; 1984 Aug; 23(8):480-3, 525. PubMed ID: 6548953
[No Abstract] [Full Text] [Related]
18. Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity.
Kendall-Taylor P
Br Med J; 1973 Jul; 3(5871):72-5. PubMed ID: 4740444
[TBL] [Abstract][Full Text] [Related]
19. The effect of partial thyroidectomy for Graves' disease on serum long-acting thyroid stimulator protector (LATS-P).
Hardisty CA; Talbot CH; Munro DS
Clin Endocrinol (Oxf); 1981 Feb; 14(2):181-8. PubMed ID: 6894891
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin levels and long-acting thyroid stimulator (LATS) in hyperthyroidism. A preliminary study.
Yamakido M; Yokoyama M; Noguchi S
Hawaii Med J; 1969; 29(2):118-9. PubMed ID: 5361480
[No Abstract] [Full Text] [Related]
[Next] [New Search]
